Frontline Acalabrutinib Plus Chemoimmunotherapy Elicits Meaningful Survival Benefit in MCL

Acalabrutinib plus bendamustine and rituximab (BR) led to a statistically significant improvement in PFS vs BR for treatment-naive mantle cell lymphoma.

Related Keywords

Japan ,Texas ,United States ,Houston ,China ,Acalabrutinib Calquence ,Susan Galbraith ,Michael Wang ,Astrazeneca ,University Of Texas Md Anderson Cancer Center ,European Union ,Mantle Cell Lymphoma Program Of Excellence ,Puddin Clarke Endowed Professor ,Mantle Cell Lymphoma Program ,Cancer Center ,Lugano Classification ,